for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sinovac Biotech Ltd.

SVA.O

Latest Trade

6.47USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

6.25

 - 

6.58

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.47
Open
--
Volume
--
3M AVG Volume
0.00
Today's High
--
Today's Low
--
52 Week High
6.58
52 Week Low
6.25
Shares Out (MIL)
98.90
Market Cap (MIL)
639.90
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Sinovac Reports Unaudited First Quarter 2020 Financial Results

Sinovac Says Positive Prelim Results Of Phase I/II Trials For COVID-19 Vaccine Candidate

Sinovac Secures $15 Mln In Funding To Accelerate COVID-19 Vaccine Development

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sinovac Biotech Ltd.

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Industry

Biotechnology & Drugs

Contact Info

39 Shangdi Xi Road, Haidian District

BEIJING, BEJ

102200

China

+86.10.82890088

http://www.sinovac.com/

Executive Leadership

WeiDong Yin

Chairman of the Board, President, Chief Executive Officer, Secretary

Nan Wang

Chief Financial Officer, Vice President

Xiaomei Yin

Vice President - Sales and Marketing

Qiang Gao

Vice President - Research and Development

Jing Li

Vice President - Quality and Production

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
2.85
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
12.13
Total Debt To Equity (MRQ)
6.90
LT Debt To Equity (MRQ)
0.50
Return on Investment (TTM)
18.68
Return on Equity (TTM)
13.30

Latest News

Latest News

China's Sinovac starts late stage trials for its COVID-19 vaccine

China's Sinovac Biotech is starting Phase III trials of its potential coronavirus vaccine in Brazil, it said on Monday, becoming one of three companies to move into the late stages in the race to develop an inoculation against the disease.

China's SinoVac starts late stage trials for its COVID-19 vaccine

China's SinoVac is starting Phase III trials of its potential coronavirus vaccine, it said on Monday, becoming one of three companies to move into the late stages in the race to develop an inoculation against the disease.

BRIEF-Sinovac Covid-19 Vaccine Collaboration With Butantan Receives Approval From Brazilian Regulator For Phase III Trial

* SINOVAC COVID-19 VACCINE COLLABORATION WITH BUTANTAN RECEIVES APPROVAL FROM BRAZILIAN REGULATOR FOR PHASE III TRIAL

Brazil health regulator Anvisa allows Chinese COVID-19 vaccine trial

Brazilian health regulator Anvisa on Friday approved clinical trials of a potential coronavirus vaccine developed by China's Sinovac <SVA.O>, according to an official gazette publication.

Brazil to test Sinovac's potential vaccine against COVID-19 in six states

A potential coronavirus vaccine developed by China's Sinovac will be tested in Brazil by 12 research centers in six Brazilian states, the governor of Sao Paulo state, Joao Doria, said on Wednesday, adding the trials still need to be approved by local health vigilance agency...

Brazil to test Sinovac's potential vaccine against COVID-19 in six states

A potential coronavirus vaccine developed by China's Sinovac will be tested in Brazil by 12 research centers in 6 Brazilian states, the governor of Sao Paulo state, Joao Doria, said on Wednesday, adding the trials still need to be approved by local health vigilance agency...

BRIEF-Sinovac Reports Unaudited First Quarter 2020 Financial Results

* SINOVAC REPORTS UNAUDITED FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Sinovac Receives Approval From China For Its Quadrivalent Influenza Vaccine

* SINOVAC RECEIVES APPROVAL FROM CHINA FOR ITS QUADRIVALENT INFLUENZA VACCINE

BRIEF-Sinovac Says Positive Prelim Results Of Phase I/II Trials For COVID-19 Vaccine Candidate

* SINOVAC ANNOUNCES POSITIVE PRELIMINARY RESULTS OF PHASE I/II CLINICAL TRIALS FOR INACTIVATED VACCINE CANDIDATE AGAINST COVID-19

Brazil research institute in deal to help test, produce Chinese coronavirus vaccine

The Butantan Institute, one of Brazil's leading biomedical research centers, on Thursday announced an agreement with China's Sinovac Biotech Ltd to potentially produce a vaccine against the new coronavirus.

BRIEF-Sinovac And Butantan Join Efforts To Advance Clinical Development Of Inactivated Vaccine For COVID-19 To Phase III

* SINOVAC AND BUTANTAN JOIN EFFORTS TO ADVANCE CLINICAL DEVELOPMENT OF AN INACTIVATED VACCINE FOR COVID-19 TO PHASE III Source text for Eikon: Further company coverage:

BRIEF-CSL Says To Acquire Biotech Company Vitaeris

* COST OF ACQUISITION DOES NOT MATERIALLY CHANGE CO'S PROFIT EXPECTATION FOR FY2020

Sinovac says it has started mid-stage human trials of COVID-19 vaccine

Sinovac Biotech Ltd said on Friday it had started mid-stage human trials of its experimental coronavirus vaccine in China earlier this month.

BRIEF-Sinovac Secures $15 Mln In Funding To Accelerate COVID-19 Vaccine Development

* SINOVAC SECURES $15 MILLION IN FUNDING TO ACCELERATE COVID-19 VACCINE DEVELOPMENT

BRIEF-Sinovac Comments On SEC Findings Against Jiaqiang "Chiang" Li And 1Globe Capital

* SINOVAC COMMENTS ON SEC FINDINGS AGAINST JIAQIANG "CHIANG" LI AND 1GLOBE CAPITAL

BRIEF-Ritter Pharmaceuticals Urges Stockholders To Vote On Proposed Merger With Biotech Company Qualigen Inc

* RITTER PHARMACEUTICALS, INC. URGES STOCKHOLDERS TO VOTE NOW ON PROPOSED MERGER WITH BIOTECH COMPANY, QUALIGEN INC. Source text for Eikon: Further company coverage:

China's Sinovac gains land and loans to speed up work on coronavirus vaccine

China's Sinovac Biotech Ltd, which has approval to begin clinical trials of an experimental vaccine for the new coronavirus, said it plans to have a new production facility ready this year after quickly obtaining land and loans.

BRIEF-Sinovac Announces Commencement Of Phase I Human Clinical Trial For Vaccine Candidate Against COVID-19

* SINOVAC ANNOUNCES COMMENCEMENT OF PHASE I HUMAN CLINICAL TRIAL FOR VACCINE CANDIDATE AGAINST COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Dynavax And Sinovac Announce Collaboration To Develop A Coronavirus Vaccine

* DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A CORONAVIRUS (COVID-19) VACCINE

BRIEF-Dynavax And Sinovac Announce Collaboration To Develop A Coronavirus Vaccine

* DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A CORONAVIRUS (COVID-19) VACCINE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up